Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Hematology
Volume 2015, Article ID 373490, 4 pages
http://dx.doi.org/10.1155/2015/373490
Case Report

JAK2V617F: Is It Sufficient as a Single Player in Splanchnic Venous Thrombosis?

Department of Hematology, Institute of Liver and Biliary Sciences, New Delhi 110070, India

Received 5 February 2015; Revised 12 March 2015; Accepted 12 March 2015

Academic Editor: Ramon Tiu

Copyright © 2015 Pratibha Dhiman and Priyanka Saxena. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Splanchnic venous thrombosis (SVT) includes thrombosis of the hepatic, portal, and mesenteric venous system. Myeloproliferative neoplasms (MPNs) are important factors of SVT in adults. Addition of JAK2V617F mutation in WHO criteria for diagnosis of MPNs has made this test a useful tool for diagnosis. JAK2 is an intracytoplasmic tyrosine kinase that plays a critical role in signal transduction from multiple hematopoietic factor receptors. The mutation is found frequently in patients with SVT; many such patients have no other manifestations of an MPN. Although the correlation of JAK2V617F mutation with thrombotic risk in MPNs has been shown in many studies, the impact of presence of additional thrombophilic factors in these cases is yet not known. As the management of MPNs remains highly dependent on the patient’s thrombotic risk, it is important to assess the thrombotic risk factors in detail. Here, we report two cases of JAK2V617F positive MPN who also had other thrombophilic conditions and presented with recurrent thrombosis.